A more realistic model for a difficult inherited heart disease
Researchers at Washington University in St. Louis have developed what they describe as the first human model of a form of desmin-related cardiomyopathy linked to the protein-folding chaperone αB-Crystallin, also known as CRYAB. The model combines micro-engineered heart tissues with induced pluripotent stem cells and is designed to express mutant CRYAB at levels close to those found in the human body.
The advance matters because inherited cardiomyopathies are a leading cause of heart failure in young adults, yet many of the rare disorders within that group remain hard to study in ways that translate well to patients. Desmin-related cardiomyopathy, or DRM, affects an estimated one in 2,000 people worldwide. There are no therapies targeted specifically at the disease; patients currently receive general heart-failure medicines.
DRM can arise from mutations in the gene for desmin, a muscle-specific intermediate filament protein, or in CRYAB, which helps proteins fold correctly. Researchers believe harmful variants can leave desmin misfolded and prone to forming toxic clumps inside heart-muscle cells. Those disruptions can interfere with the ability of the heart to contract and pump blood effectively.
Why protein levels matter
Previous experimental models have posed an important limitation. Mouse models of CRYAB-linked disease have required large overexpression of the mutant protein. That can be useful for provoking a clear laboratory effect, but it also makes interpretation more difficult. Protein clumping depends in part on interactions among proteins, and an artificially high amount of a mutant protein may create interactions that do not occur at the same scale in human disease.
The Washington University team sought to address that gap by creating human tissues with physiologically relevant expression of mutant CRYAB. Instead of relying on a system in which the mutation is amplified by unusually large protein production, the researchers built an experimental platform intended to reflect the concentration seen in people more closely.
That distinction is central to the model’s value. A disease system is not useful only because it reproduces an abnormal result; it must also help researchers distinguish which changes are likely to be fundamental to the disease from those that may be artifacts of the experimental setup. A model that more closely matches the molecular setting in patients could make it easier to identify which therapeutic strategies deserve further testing.
A platform for studying contraction and calcium handling
The engineered human tissues allow researchers to investigate how protein aggregation affects heart-muscle contraction and calcium handling. Both are essential to a working heart. Heart cells use carefully controlled calcium signals to coordinate contraction, and disruptions to that process can weaken or destabilize pumping.
By pairing patient-relevant cellular biology with micro-engineered tissue, the model creates a setting in which researchers can examine disease effects beyond an isolated protein measurement. It can connect molecular changes to the behavior of human heart tissue, including the consequences for contraction.
Nathaniel Huebsch, an associate professor of biomedical engineering at Washington University’s McKelvey School of Engineering, said progress has been constrained by models with uncertain translational value. The new system is intended to offer a human experimental setting in which mutant-protein expression is relevant to physiology, rather than simply abundant enough to force a visible phenotype.
What the model could change
The research does not itself establish a treatment for desmin-related cardiomyopathy. Its immediate contribution is a tool: a way to test potential therapies in a human tissue system that aims to reproduce a key aspect of the disease more faithfully. That could help researchers evaluate whether an intervention changes protein aggregation, improves calcium handling, restores contraction, or affects several of those processes together.
The platform may also be useful beyond one inherited disorder. The researchers describe it as a potential testing system for therapies aimed at inherited and acquired heart diseases. That broader relevance follows from the model’s focus on a recurring problem in cardiac research: linking the cellular consequences of damaged protein quality control to the mechanical performance of heart tissue.
For families affected by DRM, the work highlights a shift in emphasis from broadly managing heart-failure symptoms to building the experimental foundations for disease-specific approaches. Much more research will be required before a therapy can be shown to work in people, but a human model with realistic mutant-protein levels gives that work a more relevant place to start.
The next test is translation
The model’s importance will ultimately depend on how well it predicts results outside the laboratory. Researchers will need to use it to compare candidate interventions, determine whether promising findings hold across relevant disease variants, and establish how closely tissue responses align with patient biology.
Even so, the approach addresses a practical obstacle that has slowed the field. By avoiding dependence on massive mutant-protein overexpression, it offers a clearer route for investigating how a rare, deadly heart disorder unfolds in human tissue—and for testing whether that process can be altered.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
